2024
Beaumont, S., Magel, T., MacDonald, S., Harrison, S., Schechter, M., & Oviedo-Joekes, E. (2024). Shared decision-making and client-reported dose satisfaction in a longitudinal cohort receiving injectable opioid agonist treatment (iOAT). Substance Abuse Treatment, Prevention, and Policy, 19(1), 1. https://doi.org/10.1186/s13011-023-00585-4
Magel, T., MacNab, Y. C., MacDonald, S., & Oviedo-Joekes, E. (2024). Experiences of serious depression and serious anxiety among clients receiving injectable opioid agonist treatment (iOAT). Journal of Affective Disorders Reports, 15. https://doi.org/10.1016/j.jadr.2023.100695
2023
Adams, A., Blawatt, S., MacDonald, S., Finnick, R., Lajeunesse, J., Harrison, S., Byres, D., Schechter, M. T., & Oviedo-Joekes, E. (2023). Provider experiences with relaxing restrictions on take-home medications for opioid use disorder during the COVID-19 pandemic: A qualitative systematic review. The International Journal on Drug Policy, 117, 104058. https://doi.org/10.1016/J.DRUGPO.2023.104058
Adams, A., Blawatt, S., Magel, T., MacDonald, S., Lajeunesse, J., Harrison, S., Byres, D., Schechter, M., & Oviedo-Joekes, E. (2023). The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: A mixed methods systematic review. Substance Abuse Treatment, Prevention, and Policy, 18(1), 56.
Blawatt, S., Arreola, L. A. G., Magel, T., MacDonald, S., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2023). Changes in daily dose in open-label compared to double-blind: The role of clients’ expectations in injectable opioid agonist treatment. Addictive Behaviors Reports, 17, 100490. https://doi.org/10.1016/J.ABREP.2023.100490
Blawatt, S., Harrison, S., Byres, D., Foreman, J., Amara, S., Burdge, W., MacDonald, S., Schechter, M. T., & Oviedo-Joekes, E. (2023). The mobilization of nurse-client therapeutic relationships in injectable opioid agonist treatment: Autonomy, advocacy and action. Journal of Substance Use and Addiction Treatment, 154, 209154. https://doi.org/10.1016/J.JOSAT.2023.209154
Dobischok, S., Carvajal, J. R., Turner, K., Jaffe, K., Lehal, E., Blawatt, S., Redquest, C., Baltzer Turje, R., McDougall, P., Koch, B., McDermid, C., Hassan, D., Harrison, S., & Oviedo-Joekes, E. (2023). “It feels like I’m coming to a friend’s house”: an interpretive descriptive study of an integrated care site offering iOAT (Dr. Peter Centre). Addiction Science & Clinical Practice, 18(1), 73. https://doi.org/10.1186/s13722-023-00428-4
Dobischok, S., Guh, D., Marchand, K., MacDonald, S., Lock, K., Harrison, S., Lajeunesse, J., Schechter, M., & Oviedo-Joekes, E. (2023). The Impact of Injectable Opioid Agonist Treatment (iOAT) on Involvement in Criminalized Activities: A Secondary Analysis from a Clinical Trial in Vancouver, BC. Substance Abuse and Rehabilitation, Volume 14, 147–156. https://doi.org/10.2147/sar.s438451
Dobischok, S., Metcalfe, R., Matzinger, E., Palis, H., Marchand, K., Harrison, S., MacDonald, S., Byres, D., Schechter, M., Bansback, N., & Oviedo-Joekes, E. (2023). Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling). International Journal of Drug Policy, 112, 103948. https://doi.org/10.1016/J.DRUGPO.2022.103948
Jaffe, K., Blawatt, S., Lehal, E., Lock, K., Easterbrook, A., MacDonald, S., Harrison, S., Lajeunesse, J., Byres, D., Schechter, M., & Oviedo-Joekes, E. (2023). “As long as that place stays open, I’ll stay alive”: Accessing injectable opioid agonist treatment during dual public health crises. Harm Reduction Journal 2023 20:1, 20(1), 1–12. https://doi.org/10.1186/S12954-023-00779-W
Magel, T., Matzinger, E., Blawatt, S., Harrison, S., MacDonald, S., Amara, S., Metcalfe, R., Bansback, N., Byres, D., Schechter, M., & Oviedo-Joekes, E. (2023). How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders’ perspectives. Drugs: Education, Prevention and Policy, 1–12.
Oviedo-Joekes, E., Dobischok, S., Carvajal, J., MacDonald, S., McDermid, C., Klakowicz, P., Harrison, S., LaJeunesse, J., Chow, N., Brown, M., Gill, S., & Schechter, M. (2023). Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study. BMC Health Services Research, 23(1), 1–16. https://doi.org/10.1186/S12913-023-09558-6
2022
Dobischok, S., Metcalfe, R. K., Matzinger, E. A., Lock, K., Harrison, S., MacDonald, S., Amara, S., Schechter, M. T., Bansback, N., & Oviedo-Joekes, E. (2022). Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study. Patient Preference and Adherence, Volume 16, 3405–3413. https://doi.org/10.2147/PPA.S391532
Marchand, K., Palis, H., Guh, D., Lock, K., MacDonald, S., Brissette, S., Marsh, D. C., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2022). A multi-methods and longitudinal study of patients’ perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research. Journal of Substance Abuse Treatment, 132, 108512. https://doi.org/10.1016/J.JSAT.2021.108512
2021
Oviedo-Joekes, E., MacDonald, S., Boissonneault, C., & Harper, K. (2021). Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Substance Abuse: Treatment, Prevention, and Policy, 16(1). https://doi.org/10.1186/s13011-021-00358-x
Palis, H., Guh, D., MacDonald, S., Harrison, S., Brissette, S., Marsh, D. C., Schechter, M. T., & Oviedo-Joekes, E. (2021). Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach. Drug and Alcohol Dependence, 218. https://doi.org/10.1016/J.DRUGALCDEP.2020.108333
2020
Marchand, K., Foreman, J., MacDonald, S., Harrison, S., Schechter, M. T., & Oviedo-Joekes, E. (2020). Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Substance Abuse: Treatment, Prevention, and Policy, 15, 1–9. https://doi.org/10.1186/s13011-020-0253-y
2019
Oviedo-Joekes, E., Palis, H., Guh, D., Marsh, D. C., MacDonald, S., Harrison, S., Brissette, S., Anis, A. H., & Schechter, M. T. (2019). Adverse Events During Treatment Induction With Injectable Diacetylmorphine and Hydromorphone for Opioid Use Disorder. Journal of Addiction Medicine, 13(5), 354. https://doi.org/10.1097/ADM.0000000000000505
Oviedo-Joekes, E., Palis, H., Guh, D., Marchand, K., Brissette, S., Harrison, S., MacDonald, S., Lock, K., Anis, A. H., Marsh, D. C., & Schechter, M. T. (2019). Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods. Journal of Substance Abuse Treatment, 101, 50–54.
2018 and earlier
Bansback, N., Guh, D., Oviedo-Joekes, E., Brissette, S., Harrison, S., Janmohamed, A., Krausz, M., MacDonald, S., Marsh, D. C., Schechter, M. T., & Anis, A. H. (2018). Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial. Addiction, 113(7), 1264–1273. https://doi.org/10.1111/add.14171
Oviedo-Joekes, E., Marsh, D. C., Guh, D., Brissette, S., & Schechter, M. T. (2011). Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency. Journal of Opioid Management, 7(5), 371–376. https://doi.org/10.5055/jort.2O1
Oviedo-Joekes, E., Brissette, S., Marsh, D. C., Lauzon, P., Guh, D., Anis, A., & Schechter, M. T. (2009). Diacetylmorphine versus Methadone for the Treatment of Opioid Addiction. The New England Journal of Medicine, 361(8), 786. https://doi.org/10.1056/NEJMOA0810635